Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters

New Strategy Head Will Seek Higher Earning Innovation

 
• By Andrew McConaghie

Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.

Novartis
Novartis is the leader in number of new approvals in recent years - but does not have a big-earning blockbuster like Trulicity or Keytruda to power its US sales. • Source: Alamy

More from Business

More from Scrip